- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00458562
Identifying Genes That Predict Risk of Developing Cervical Intraepithelial Neoplasia or Invasive Cervical Cancer
HIV-Associated DNA Hypermethylation in Cervical Cancer
RATIONALE: Finding certain changes in genes may help doctors predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer and may help the study of cancer in the future.
PURPOSE: This clinical trial is studying genes that may predict which patients are at risk of developing cervical intraepithelial neoplasia or invasive cervical cancer.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
OBJECTIVES:
- Utilize molecular assays to identify a panel of hypermethylated genes that are predictive of cervical intraepithelial neoplasia (CIN) grade 3 or invasive cervical cancer (ICC) among patients with or without HIV infection.
- Perform a nested case-control study assessing the risk of developing CIN3 in relationship to human papillomavirus (HPV) persistence, HIV, and the presence or acquisition of candidate hypermethylated genes in these patients.
- Identify HIV-related factors (e.g., CD4 counts, viral load, and highly active antiretroviral therapy [HAART]) that might be associated with the presence or acquisition of specific hypermethylated genes in these patients.
OUTLINE: This is a longitudinal, multicenter study.
Patients undergo biopsy for removal of cervical tissue. Patients also undergo blood and urine sample collection. Samples are analyzed for the presence of cancer or changes that indicate that cancer might develop. Patients also undergo colposcopy at baseline and at 3 years.
After completion of study procedures, patients are followed every 4 months for up to 3 years.
PROJECTED ACCRUAL: A total of 1,150 patients will be accrued for this study.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Dakar, Senegal, BP 5035
- Centre Hospitalier Universite De Fann
-
Dakar, Senegal, BP 5126
- Hôpital Aristide Le Dantec
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
INCLUSION CRITERIA:
Underwent Pap smear, human papillomavirus (HPV) testing, and HIV testing AND meets any of the following criteria:
Biopsy and colposcopy confirmed cervical intraepithelial neoplasia (CIN) or invasive cervical cancer (ICC), meeting any of the following criteria:
- CIN grade 2-3 or higher
- Repeated CIN1 (times 6)
- Abnormal Pap smear (atypical squamous cells of undetermined significance [ASCUS] or worse)
- HIV seropositive
- Negative cytology but positive for high-risk human papillomavirus (HPV)
- Negative cytology and negative HPV
- HIV negative (without biopsy-proven CIN 3 or worse) and high-risk HPV infection (types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 55, 56, 58, 59, 68, 82, 83, 73)
- >= 18 years of age
- Intact cervix
- Not pregnant
- Able to provide informed consent
EXCLUSION CRITERIA:
- < 18 years of age
- Pregnant at screening
- Cervix not intact
- not able to provide informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
HIV+, <CIN2
HIV positive women without CIN2-3 or worse
|
HIV-, no >=CIN3 biopsy, HR HPV+
HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
|
HIV-, <=CIN1, HPV- at screening
HIV negative women who are <= CIN1 and HPV negative at screening
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Identification of hypermethylated genes that are predictive of cervical intraepithelial neoplasia (CIN) grade 3 or invasive cervical cancer
Tidsramme: 3 years
|
Use molecular assays to identify a panel of hypermethylated genes that are predictive of CIN-3/ICC among women with and without HIV infection.
We will rank genes by their ability to discriminate normal cervical tissue from CIN-3/ICC after stratifying by HIV infection.
|
3 years
|
Assessment of the risk of developing CIN3 in relationship to human papillomavirus (HPV) persistence, HIV, and the presence or acquisition of candidate hypermethylated genes
Tidsramme: 3 years
|
Perform a nested case control study assessing the risk of developing CIN-3 in relationship to HPV persistence, HIV, and the presence or acquisition of the candidate hypermethylated genes.
|
3 years
|
Identification of HIV-related factors associated with the presence or acquisition of specific hypermethylated genes
Tidsramme: 3 years
|
Identify HIV-related factors (CD4 counts, viral load, HAART) which might be associated with the presence or acquisition of specific hypermethylated genes.
|
3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Nancy B. Kiviat, MD, Harborview Injury Prevention and Research Center
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Karsinom
- Neoplasmer, kjertel og epitel
- Uterine neoplasmer
- Genitale neoplasmer, kvinnelige
- Livmor livmorhalssykdommer
- Livmorsykdommer
- Karsinom in situ
- Uterine cervikale neoplasmer
- Cervikal intraepitelial neoplasi
- Forstadier til kreft
Andre studie-ID-numre
- 6113
- P30CA015704 (U.S. NIH-stipend/kontrakt)
- R01CA111187 (U.S. NIH-stipend/kontrakt)
- UWCC-6113 (Annen identifikator: Fred Hutchinson/University of Washington Cancer Consortium)
- UWCC-04-4928-B01 (Annen identifikator: Fred Hutchinson/University of Washington Cancer Consortium)
- FHCRC-6113 (Annen identifikator: Fred Hutchinson/University of Washington Cancer Consortium)
- CDR0000482330 (Registeridentifikator: PDQ)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Livmorhalskreft
-
Ohio State UniversityMedtronicRekrutteringCervical FusionForente stater
-
Wang YuchengUkjentCervical Spondylose av Cervical TypeKina
-
Zagazig UniversityRekrutteringCervical Spine SurgeryEgypt
-
Assiut UniversityHar ikke rekruttert ennåCervical Spine Fusion
-
Research SourcePåmelding etter invitasjonCervical disc sykdomForente stater
-
Ataturk UniversityFullført
-
Duke UniversityUniversity of ArkansasFullført
-
China Medical University HospitalHar ikke rekruttert ennå
-
Zagazig UniversityFullførtCervical Spine SurgeryEgypt
-
NYU Langone HealthFullført